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Abstract
Background: Head and neck cancer (HNC) is a debilitating disease due in part to its effects on function,
including speech, swallowing, and cosmesis. Previous studies regarding depression in HNC have focused on
demographic predictors, incidence, and quality of life studies. There is, however, a paucity of studies that
objectively address depressive symptoms in HNC patients and the resultant effects on post-treatment
functional performance status. The aim of this study was to assess the relationship between preoperative
depressive symptoms (PDS) and postoperative functional performance status (PFPS), in addition to other
predictors of rehabilitation and survival.
Methods: A prospective cohort study was undertaken at the University of Alberta, including all new adult
HNC patients undergoing surgery as primary therapy for HNC from May 2013 to January 2014. Baseline
depressive symptoms were measured on the Quick Inventory of Depressive Symptoms (QIDS) questionnaire
2 weeks preoperatively and PFPS was assessed 12 months postoperatively on the Functional Assessment of
Cancer Therapy-Head & Neck (FACT-HN) scale. Secondary outcomes included completion of adjuvant therapy,
narcotic dependence, return to detrimental habits, loss of follow-up, and length of hospital stay (LOHS).
Differences between the Normal-Mild and Moderate-Severe QIDS groups were assessed using Mann–Whitney
and Fischer Exact statistical analyses.
Results: Seventy-one patients were included in the study. Mild and Moderate-Severe PDS were 35.2 % and 18.3 %,
respectively. Significantly lower FACT-HN scores were noted in the Moderate-Severe group at 12 months (p = 0.03). The
risk ratio (RR) for FACT-HN score < 50 % at 12 months in the Moderate-Severe group was 5.66. In addition, significantly
lower completion of adjuvant treatment (p = 0.03), significantly higher incidence of narcotic dependence (p = 0.004),
and significantly higher LOHS (24 days vs. 18 days; p = 0.02) was observed in the Moderate-Severe group. There was no
significant difference in loss of follow-up between the 2 groups (p = 0.64).
Conclusions: The incidence and severity of PDS in HNC patients treated with surgery is high (53.5 %). Patients with
Moderate-Severe PDS have significantly decreased PFPS, increased narcotic use, decreased completion of adjuvant
therapy, and a longer LOHS. HNC patients should be monitored closely for depressive symptoms.
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Introduction
Head and neck cancer (HNC) is a debilitating disease due
in part to its effects on daily patient function including
speech, swallowing, and cosmesis. Previous studies have
demonstrated that approximately 40 % of patients become
depressed in the first year after their diagnosis and treat-
ment for head and neck cancer, and more importantly,
this goes unrecognized and untreated [1]. Misono et al. [2]
revealed that oral cavity and laryngeal cancer make up 2
of the 4 highest suicide populations amongst cancer pa-
tients. These finding may be attributed to the devastating
combination of predisposing factors for HNC, incapacitat-
ing symptoms, and the sequelae of treatment.
Depression is also a devastating disease robbing patients
of function and quality of life. Previous studies regarding
depression in HNC have focused on demographic predic-
tors, incidence, and quality of life studies. There is, how-
ever a paucity of studies that objectively address depressive
symptoms in the HNC patients and their effect on post-
treatment functional performance status. Limited literature
exists regarding the effect of depression on other factors
that may affect rehabilitation and survival, such as comple-
tion of adjuvant treatment and return to detrimental habits.
The aim of this study was to assess the relationship
between preoperative depressive symptoms (PDS) and
postoperative functional performance status (PFPS), in
addition to other predictors of rehabilitation and
survival.
Methods
Institutional ethical approval was obtained from the
Human Research Ethics Board (HREB) at the University of
Alberta. Informed consent was obtained from all participat-
ing subjects.
A prospective cohort study of HNC patients presenting
to a tertiary cancer care practice at the University of
Alberta Hospital was undertaken. The study population
consisted of adult patients undergoing major head and
neck ablative and reconstructive surgery and adjuvant
therapy for a new HNC. HNCs considered eligible for in-
clusion were mucosal squamous cell carcinoma (SCC),
salivary gland tumors, and skin cancers. Thyroid and ocu-
lar cancers were excluded from the study given differences
in the extent of surgical management for each group. Pa-
tients were recruited at the time of preoperative surgical
education sessions approximately 2 weeks prior to surgery
from September 1, 2013 to March 1, 2014.
Demographic assessment
Adult patients undergoing surgery and adjuvant radio-
therapy for a new HNC were included. Patients with a
pre-existing psychiatric history, those who were unable
to read or comprehend the questionnaires or lacked
capacity to consent, and those unwilling to present for
follow-up questionnaires or assessment were excluded.
Demographic data regarding age, gender, comorbidi-
ties, primary tumor site and stage, pre-treatment sub-
stance abuse, and presence of supportive caregivers
was collected. Advanced-stage cancers were defined as
those tumors with a clinical T-stage greater than 2 or
N-stage greater than 0. Patient comorbidities were
identified and Charlson Comorbidity Index was calcu-
lated for each patient.
Preoperative depressive symptom (PDS) assessment
Once determined eligible, patients underwent baseline
evaluation with the Quick Inventory of Depressive
Symptomatology Self-Report (QIDS-SR) questionnaire
[3]. This is a self-report, validated questionnaire involv-
ing 16 items under the typical 9 domains assessed with
regard to depressed mood. This was not utilized as a
diagnostic test for depression, but as a screening tool
for examining the severity of depressive symptoms. The
QIDS-SR is scored from 0 to 27, and patients were clas-
sified as normal, mild, moderate, severe (Table 1), with
higher scores indicative of more severe depressive
symptoms. Previous studies have demonstrated an in-
ternal consistency between physician-rated QIDS-SR
score and self-report scores as high as 0.94 [4].
The Functional Assessment of Cancer Therapy for
Head and Neck patients (FACT-HN) is a multi-
dimensional, self-reported assessment of post-treatment
functional performance status that was specifically de-
signed for head and neck cancer patients, and has been
used extensively in Radiation Therapy Oncology Group
(RTOG) trials [5–7]. Social, emotional, physical, family,
and well-being domains are addressed, and questions re-
lated to these domains are answered on a 5-point Likert
scale by the patients. Questionnaires are scored from 0 to
144 with higher scores representative of better function-
ing. Scores of less than 50 % on the FACT-HN correlate
with clinical functional decline [5]. A previous analysis of
test-retest reliability regarding the stability of the stand-
alone FACT-HN questionnaire has demonstrated an intra-
class correlation of 0.89 [8].
Table 1 Scoring rubric for QIDS-SR questionnaire as previously







QIDS-SR Quick Inventory of Depressive Symptomatology-Self Report
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Outcome measures
The primary outcome assessed was the FACT-HN score
12 months postoperatively. Secondary outcomes were
those not evaluated in previous literature, including com-
pletion of adjuvant therapy (defined as completion of all
adjuvant treatments including chemotherapy and radio-
therapy), narcotic dependence (defined as persistent use
greater than 3 months postoperatively), and loss of follow-
up (defined as patients not presenting for 2 consecutive
scheduled follow-up appointments with no attempts to re-
schedule). Return-to-habit status was defined as a postop-
erative return to detrimental habits, such as tobacco,
alcohol, or illicit drug abuse. Length of hospital stay
(LOHS) was also calculated for each patient and com-
pared between groups.
After patients were determined eligible for the study,
they underwent a baseline QIDS-SR assessment approxi-
mately 2–3 weeks prior to surgery during routine pre-
operative surgical education sessions. Patients were then
classified into the Normal-Mild group (0–10) or the
Moderate-Severe group (11–27) based on the scores dem-
onstrated in Table 1. Subsequently, the patients under-
went resection and reconstructive surgery with routine
postoperative care including adjuvant therapy. Follow-up
appointments were arranged for 2 weeks, 3, 6, and
12 months postoperatively, as is standard protocol. Pa-
tients were reassessed at 12 months postoperatively
with both a QIDS and FACT-HN assessment. Second-
ary outcomes were also assessed at 12 months.
Treatment for depressive symptoms was initiated in
the standard clinical fashion, but was not considered
part of this observational study. If patients scored in the
Mild category, a discussion regarding depressive symp-
toms was initiated and patients were referred to Psych-
iatry for assessment upon request. If patients scored in
the Moderate or Severe groups, they were referred to
Psychiatry for assessment and options for treatment
were discussed with the patient. Outcomes of treatment
discussion with Psychiatry were recorded and followed
for the Moderate-Severe group.
Statistical analysis
The Normal-Mild group was compared to the Moderate-
Severe group regarding FACT-HN scores using a Mann–
Whitney analysis. A multiple regression analysis was add-
itionally performed using other known predictors of post-
operative functional performance status to assess the
predictive value of PDS on PFPS. A risk ratio (RR) was
also calculated for a score less than 50 % on the FACT-
HN for those patients with Moderate-Severe PDS [5]. Sec-
ondary outcomes were assessed using a Fischer Exact ana-
lysis as well as a Spearman Correlation analysis to confirm
statistically significant findings. LOHS was compared be-
tween groups using a Mann–Whitney analysis. Normal-
Mild and Moderate-Severe groups were also compared
regarding demographic variables, comorbidities, pre-
treatment ETOH or illicit drug use, supportive care-
givers, and tumor sites, and TNM-staging using
Mann–Whitney and Fisher exact analyses. Statistical
analysis was performed using SPSS software (SPSS,
Version 21.0, Chicago, IL).
Results
Seventy-five patients were approached for recruitment
to the study; 1 refused participation, 2 did not fully
complete the baseline QIDS questionnaire, and 1 did
not undergo adjuvant therapy. The compliance rate for
baseline PDS assessment was thus 96 % (72 of 75
patients). Of the 71 patients eligible for participation,
58 patients (81.7 %) scored in the Normal-Mild range
upon baseline assessment, with the remaining 13 (18.3 %)
scoring in the Moderate-Severe group.
Initial examination of demographic data for the entire
cohort revealed findings typical of the HNC population,
with a mean age of 59.7, a male gender predominance
(70.4 %), and primarily advanced-stage disease (90.1 %).
The Charlson Comorbidity Index (CCI) for the entire
cohort was 70.2 %. Further examination of each study
group revealed no differences in mean age, gender,
TNM staging, cancer site, reconstruction, adjuvant
therapy, pre-treatment substance abuse, presence of
supportive care-givers, or Charlson Comorbidity Index
between the Normal-Mild and Moderate-Severe groups
(Table 2).
At baseline 35.2 % of patients displayed Mild-only
depressive symptoms and 18.3 % of patients displayed
Moderate-Severe depressive symptoms. None of the
patients expressed or recorded thoughts of suicidal
ideation. More extensive evaluation of the domains of
the QIDS questionnaire revealed significantly higher
scores in the sleep, mood, appetite, concentration, en-
ergy level, and psychomotor domains for the Moderate-
Severe group, indicating dysfunction in these specific
areas (Table 3).
There were no statistically significant differences
between baseline and 12-month QIDS scores in the
Normal-Mild (p = 0.67), or Moderate-Severe groups
(p = 0.58) (Table 4). FACT-HN scores at the 12th post-
operative month demonstrated a statistically signifi-
cant difference between subjects in the Normal-Mild
and Moderate-Severe groups (p = 0.03). A multiple
regression analysis was performed including other
known and collected predictors of PFPS, which dem-
onstrated Moderate-Severe PDS as a statistically sig-
nificant predictor of postoperative FACT-HN scores
(Table 5). The risk ratio for FACT-HN score less than
50 % with Moderate-Severe PDS was calculated to
be 5.66.
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Analysis of the secondary outcomes revealed a signifi-
cantly lower rate of completion of adjuvant therapy in
the Moderate-Severe group when compared to the
Normal-Mild group (χ2 = 6.1, p = 0.03). A statistically
higher rate of narcotic dependence was found in the
Moderate-Severe group (χ2 = 8.8, p < 0.01). Higher rates
of return-to-habit status were identified in the
Moderate-Severe group (50 %) as compared to the
Normal-Mild group (10.7 %). These results were not sig-
nificant using a Fisher Exact analysis, though a trend
was evident (χ2 = 3.7, p = 0.05). No statistically signifi-
cant difference was noted between groups regarding loss
of follow-up (χ2 = 0.67, p = 0.64) (Table 6). The mean
LOHS for patients in the Moderate-Severe group was
significantly longer than the Normal-Mild group
Normal-Mild group (18 vs 24 days, p = 0.02).
Interventions for patients with Moderate-Severe symp-
toms are summated in Table 7. Of the patients in the
Moderate-Severe group, 5 (38.5 %) were deceased at
12 months, and 4 (30.8 %) were living with recurrence.
In the Normal-Mild group, 21 patients (30.0 %) were liv-
ing with recurrence at 12 months, thus no difference in
recurrence was detected between groups at 12 months
(χ2 = 2.1, p = 0.22). However, both disease-specific (DSS)
Table 2 Demographic and disease-specific findings for entire cohort and individual study groups
Variable Entire cohort (n = 71) Normal-Mild (n = 58) Moderate-Severe (n = 13) P-value
Average age 59.7 60.4 59.7 0.79
Gender
Males 50 (70.4 %) 46 (79.3 %) 8 (61.5 %) 0.65
Females 21 (29.6 %) 12 (20.7 %) 5 (38.5 %) 0.51
TNM staging
Early 7 (9.9 %) 12 (20.7 %) 3 (23.1 %) 0.35
Advanced 64 (90.1 %) 46 (79.3 %) 10 (76.9 %) 0.32
Site
Oral Cavity/Oropharynx 39 (54.9 %) 29 (50.0 %) 10 (76.9 %) 0.07
Larynx 9 (12.7 %) 9 (15.5 %) 0 (0.0 %) 0.11
Other 23 (32.4 %) 20 (34.5 %) 3 (23.1 %) 0.32
Reconstruction
Osseocutaneous FF 11 (15.5 %) 9 (15.5 %) 2 (15.4 %) 1.00
Fasciocutaneous FF 58 (81.7 %) 48 (82.8 %) 10 (76.9 %) 0.24
Pedicled/Rotational 2 (2.8 %) 1 (1.7 %) 1 (7.7 %) 0.35
Adjuvant therapy
Radiation therapy (RT) 57 (80.3 %) 46 (79.3 %) 11 (84.6 %) 0.56
Chemotherapy (C) 32 (45.1 %) 26 (44.8 %) 6 (46.2 %) 0.22
Chemoradiation Therapy (CRT) 32 (45.1 %) 26 (44.8 %) 6 (46.2 %) 0.22
Pre-treatment substance abuse 16 (22.5 %) 15 (25.9 %) 1 (7.7 %) 0.82
Supports/Caregivers available 61 (85.9 %) 48 (82.8 %) 11 (84.6 %) 0.81
Charlson comorbidity index Mean 70.2 %, Median 77 % Mean 70.2 %, Median 77 % Mean 70.2 %, Median 90 % 0.65
FF free flap, RT radiation therapy, CRT chemoradiation therapy, C chemotherapy
Table 3 Mean QIDS-SR scores at baseline and 12 months post-






Normal-Mild 5.35 8.13 0.67
Moderate-Severe 14.8 17.1 0.58
QIDS-SR Quick Inventory of Depressive Symptomatology-Self Report
Table 4 Baseline preoperative depressive symptoms (PDS)
demonstrating significant differences between Normal-Mild and
Moderate-Severe groups in 6 of 9 domains on the QIDS-SR
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and overall survival (OS) were statistically significantly
worse in the Moderate-Severe group at 12 months
(p = 0.00, p = 0.00) (Table 8, Fig. 1). No non-cancer-related
deaths occurred within 12 months of follow-up.
Discussion
This study demonstrates that the baseline prevalence and
severity of preoperative depressive symptoms is high
(53.5 %) in HNC patients, and that moderate or severe pre-
operative depressive symptoms is associated with lower
overall postoperative functional performance status, higher
rates of narcotic dependence, decreased treatment adher-
ence, and a longer length of hospital stay. This relationship
is independent of demographic factors, tumor site, TNM
staging, surgical reconstruction, type or presence of
adjuvant treatment, and medical comorbidities. These
preliminary findings suggest that depressive symptoms in
HNC patients impart significant effects on post-treatment
rehabilitation and potentially overall survival.
Postoperative functional performance status (PFPS)
has broad implications for postoperative course in
HNC patients, given the extensive rehabilitation re-
quired for swallowing, speech, wound/stoma mainten-
ance, and upper extremity physiotherapy. Moreover,
functional status can impact ability to physically attend
adjuvant treatments, and this can be compounded by
depressive symptoms. As such, PFPS and depressive
symptoms alike should be examined as contributors to
survival, given their association with low treatment
adherence in other types of cancer [9, 10]. This study
demonstrates a significantly lower post-treatment
functional status in patients displaying Moderate-Severe
PDS, with a RR of 5.66 in obtaining a score less than 50 %
on the FACT-HN questionnaire 12 months postopera-
tively. A similar study by Lin et al. [11] examined the rela-
tionship between severe depressive symptoms and specific
swallowing and speech outcomes using the MD Anderson
Dysphagia Inventory (MDADI) and Beck Depression
Inventory Fast Screen (BDI-FS), and found significantly
lower MDADI scores for depressed patients 1 year post-
treatment. This study also demonstrated a lower overall
quality of life (QOL) in patients with lower BDI –FS
scores at this time interval. Although it was not our ex-
press intention to examine QOL with increasing severity
of PDS, previous studies have correlated decreasing
FACT-HN scores with decreasing QOL, which in turn has
been shown to be a significant prognostic factor in HNC
survival [12].
Narcotic dependence was found to be significantly
associated with PDS (p = 0.004). In the Moderate-
Severe group, 4 of the 8 patients remaining alive had
recurrence, which may have contributed to the in-
creased incidence of narcotic dependence. However,
there was no significant difference between the
Normal-Mild and Moderate-Severe groups regarding
recurrence at 12 months, thus this confounder should
be eliminated. The relationship between narcotic depend-
ence, pain, PDS, and PFPS is not clear. It is possible that pa-
tients with more severe PDS have chronic pain throughout
the treatment process that contributes to a decreased PFPS.
A previous study by Shuman et al. [13] showed that severe
depressive symptoms were a significant predictor of pain in
head and neck cancer patients 1-year post-treatment. Con-
versely, other authors [14] have demonstrated an inverse re-
lationship wherein pain is a predictor of depression in post-
Table 5 Multiple regression analysis including other known
predictors of PFPS as measured on the FACT-HN, demonstrating






Charlson Comorbidity Index 0.73
Moderate-Severe Preoperative Depressive Symptoms (PDS) 0.03*
*denotes statistical significance
Table 6 Relationship between PDS and secondary outcomes
using Fisher Exact analysis
Variable P-value
Completion of adjuvant therapy 0.01*
Narcotic dependence <0.01*
Return-to-habit 0.05
Loss of Follow-up 0.64
*denotes statistical significance






4 Refused antidepressant; anxiolytic Deceased
5 Antidepressant + anxiolytic Deceased
6 Antidepressant + anxiolytic Living; recurrence
7 Antidepressant + anxiolytic Living
8 Refused antidepressant; anxiolytic Living; recurrence
9 Antidepressant Living
10 Antidepressant Living
11 Refused antidepressant; anxiolytic Deceased
12 Antidepressant + anxiolytic Living; recurrence
13 Antidepressant + anxiolytic Living; recurrence
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Table 8 Locoregional recurrence, disease-specific survival, and overall survival in Normal-Mild and Moderate-Severe groups
12 months post-treatment
Variable Entire cohort (n = 71) Normal-Mild (n = 58) Moderate-Severe (n = 13) p-value
Recurrence 25 (35.2 %) 21 (36.2 %) 4 (30.8 %) 0.22
Disease-Specific Survival (DSS) 59 (83.1 %) 51 (87.9 %) 8 (61.5 %) <0.01
Overall Survival (OSS) 51 (87.9 %) 51 (87.9 %) 8 (61.5 %) <0.01
DSS disease-specific survival, OS overall survival
Fig. 1 Kaplan-Meier curves illustrating disease-specific and overall survival (identical) for the Normal-Mild and Moderate-Severe groups after 12 months for:
a) early-stage (Stage 1 and 2) and, b) advanced-stage (Stage 3 or 4) HNCs
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treatment cancer survivors. Therefore, it can be inferred
that these symptoms can occur in parallel, and should be
monitored throughout diagnosis and treatment.
There was a near-significant relationship between PDS
and a return to detrimental habits in our HNC popula-
tion (p = 0.05). There is a well-established relationship
between addictions and mental illness, and thus, this
relationship, although marginal in this study, is not
unexpected. No significant difference in pre-treatment
substance abuse was detected between groups that could
have been considered to contribute to QIDS scores or
even treatment adherence. A recent study by Berg et al.
[15] demonstrated that, among survivors of all smoking-
related cancers, severe depressive symptoms were a sig-
nificant risk factor for continued tobacco use, yet it is
not known how much this relationship may contribute
to survival and recurrence in this population of patients.
A previous study by Jerjes et al. [16] demonstrated a sig-
nificant reduction in mortality at 3 and 5 years with alco-
hol and tobacco cessation when compared to patients
engaging in persistent use. Surveillance and treatment for
severe depressive symptoms is potentially warranted, given
the tendency of HNC patients for relapse into detrimental
habits and the impact of this on survival.
Perhaps the most compelling finding in this study is a
significant reduction in treatment adherence by patients
in the Moderate-Severe study group. While it is known
that substance abuse is common in the HNC population,
and may therefore contribute to decreased treatment ad-
herence, our results demonstrated that there was no dif-
ference in preoperative substance abuse between groups,
yet treatment adherence was significantly worse in the
Moderate-Severe group. A previous study by Lazure et al.
[17] demonstrated that HNC patients with a diagnosis of
major depressive disorder (MDD) have a 25 % greater
mortality than non-depressed patients, independent of
TNM staging. However, the cause for this significant re-
duction in survival was not clear. A multi-factorial explan-
ation is probable, given the complexity of treatment
modalities and postoperative rehabilitation in HNC. Fail-
ure of completion of adjuvant therapy is certain to con-
tribute to this mortality rate, as it is known that timely
completion of radiation therapy is an important predictor
of successful disease control [18–20]. Our study demon-
strated a significantly lower disease-specific (DSS) and
overall survival (OS) in the Moderate-Severe group, how-
ever with only 12 months of follow-up. This suggests that
any potential contribution to decreased survival rates
imparted by depressive symptoms likely affects patients
early, and potentially in the capacity of completion of ad-
juvant therapy. However, longer follow-up and further
study is required to make this association.
The limitations of this study are its relatively small
sample size and single-institution status. Future studies
should aim to examine this condition in large cohorts in
a multi-institutional manner. In addition, this was an ex-
clusively surgical cohort of patients. We elected to in-
clude only surgical patients in our study due to the
unique nature of their cosmetic concerns postoperatively
and the potential differences in symptoms they may have
compared to non-surgical patients. Future study should
consider non-surgical patients to determine differences
or similarities in optimal treatment regimens for both
groups. As well, patients with “Mild” symptoms were in-
cluded in analysis with “Normal” patients. This decision
was made in psychiatric consult, as it was reasoned that
the clinical manifestations of Moderate-Severe depression
would be more likely to cause functional disability, and
also be the cutoff for consideration of treatment. Lastly,
this study involves relatively short follow-up of 12 months.
This endpoint was chosen given the “acute” nature of the
first 12 months after treatment, and the fact that often,
12 months postoperatively is often when patients consider
a return to work. In addition, stated survival results are
done so with cautionary connotation, as they apply in the
context of 12-month follow-up. Continued study of the
functional and survival status of the cohort is ongoing,
and a screening and treatment algorithm has been in-
tegrated into the HNC clinical care pathway at the
University of Alberta to ensure sustained progress.
Conclusions
The prevalence of preoperative depressive symptoms is
high in HNC patients. The effect of PDS on post-treatment
functional status and rehabilitation, as well as treatment ad-
herence, can act as significant contributing factors in post-
operative course, and given these findings, early screening
and intervention to avert the effects of moderate or severe
depressive symptoms on postoperative rehabilitation should
be considered.
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